A low dosage of the dopamine D2-receptor antagonist sulpiride affects effort allocation for reward regardless of trait extraversion.

Approach motivation Dopamine EEfRT Sulpiride Trait extraversion

Journal

Personality neuroscience
ISSN: 2513-9886
Titre abrégé: Personal Neurosci
Pays: England
ID NLM: 101718316

Informations de publication

Date de publication:
2020
Historique:
received: 09 12 2019
revised: 23 04 2020
accepted: 24 04 2020
entrez: 14 7 2020
pubmed: 14 7 2020
medline: 14 7 2020
Statut: epublish

Résumé

Dopamine (DA) is known to be involved in various aspects of reward processing and goal-directed behavior. The present preregistered study aims at directly accessing the causal influence of DA activity on reward motivation in humans, while also accounting for trait extraversion. Therefore, we examined the effect of a single dose of the DA D2 receptor antagonist sulpiride (200 mg) on effort allocation in a modified version of the Effort-Expenditure for Reward Task (EEfRT). Based on its presumably DA increasing action, we expected the low dose of sulpiride to increase participants' willingness to allocate effort during the modified EEfRT relative to placebo, especially in trials with low probability of reward attainment. Further, we expected a moderating effect of trait extraversion on the effects of sulpiride. Two hundred and three healthy male participants were tested in a randomized, double-blind between-subjects design. Contrary to our expectations, sulpiride reduced the average number of clicks within the modified EEfRT and did not interact with reward attributes, suggesting a more global and not reward-specific effect of sulpiride. Furthermore, trait extraversion did not moderate the effect of sulpiride. Our results provide initial support for the validity of the modified version of the EEfRT, suggesting a possible inhibiting effect of a low dose of sulpiride on approach motivation regardless of trait extraversion. However, given the mixed pattern of findings and the possible confounding role of motoric abilities, further studies examining these effects are clearly warranted.

Identifiants

pubmed: 32656492
doi: 10.1017/pen.2020.7
pmc: PMC7327436
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e7

Informations de copyright

© The Author(s) 2020.

Références

Cogn Emot. 2016;30(3):458-71
pubmed: 25759131
Pharmacopsychiatry. 1999 Jul;32(4):127-35
pubmed: 10505482
Trends Cogn Sci. 2013 Jun;17(6):281-6
pubmed: 23623264
Schizophr Bull. 2015 Sep;41(5):1055-65
pubmed: 26209546
J Neurosci. 2010 Aug 18;30(33):11096-103
pubmed: 20720117
Curr Behav Neurosci Rep. 2015 Sep;2(3):146-153
pubmed: 26525751
Behav Brain Res. 1994 Dec 15;65(2):221-9
pubmed: 7718155
Psychiatry Res. 2014 Dec 30;220(3):874-82
pubmed: 25262638
Biometrics. 1986 Mar;42(1):121-30
pubmed: 3719049
Neuropsychopharmacology. 2018 Oct;43(11):2180-2189
pubmed: 30082890
J Neurosci. 2017 Feb 15;37(7):1708-1720
pubmed: 28202786
Science. 2015 Aug 28;349(6251):aac4716
pubmed: 26315443
Psychol Sci. 2013 Apr;24(4):489-97
pubmed: 23447558
Psychophysiology. 2018 Jan;55(1):
pubmed: 28459501
Eur Neuropsychopharmacol. 2019 May;29(5):629-642
pubmed: 30879927
Psychopharmacology (Berl). 2015 Apr;232(7):1313-23
pubmed: 25323625
Transl Psychiatry. 2016 Jul 05;6(7):e850
pubmed: 27378550
J Neurosci. 2015 Mar 4;35(9):4104-11
pubmed: 25740537
J Neurosci. 2011 Nov 2;31(44):15818-25
pubmed: 22049425
Psychopharmacology (Berl). 2007 Apr;191(3):483-95
pubmed: 17119929
J Pers Soc Psychol. 2002 May;82(5):804-18
pubmed: 12003479
Neuroscience. 2014 Dec 12;282:13-22
pubmed: 24463000
Neurosci Biobehav Rev. 2011 Jan;35(3):537-55
pubmed: 20603146
Neuroimage. 2005 May 1;25(4):1133-45
pubmed: 15850731
J Pharmacol Exp Ther. 1999 Feb;288(2):774-81
pubmed: 9918588
Cell. 1995 Dec 29;83(7):1197-209
pubmed: 8548806
Eur Neuropsychopharmacol. 2011 Mar;21(3):282-6
pubmed: 21112746
J Neurosci. 2017 Jun 21;37(25):6087-6097
pubmed: 28539420
J Pers Soc Psychol. 2006 Jul;91(1):171-87
pubmed: 16834487
Pharmacol Rev. 2011 Mar;63(1):182-217
pubmed: 21303898
J Neurochem. 1975 Apr;24(4):707-10
pubmed: 1123624
Schizophr Bull. 2013 May;39(3):673-83
pubmed: 22315480
Brain Res. 1983 Mar 28;264(1):105-10
pubmed: 6133578
Psychophysiology. 2018 Jan;55(1):
pubmed: 28306164
Curr Top Behav Neurosci. 2016;27:231-57
pubmed: 26323245
Clin Neuropharmacol. 1990;13 Suppl 1:S76-83
pubmed: 2199037
Mol Psychiatry. 2005 Jan;10(1):79-104
pubmed: 15289815
J Neurosci. 2011 Nov 16;31(46):16597-602
pubmed: 22090487
Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 2):2649-65
pubmed: 24035741
Front Neural Circuits. 2013 Oct 11;7:152
pubmed: 24130517
Schizophr Bull. 2015 Sep;41(5):1045-54
pubmed: 26142081
PLoS One. 2015 Jun 26;10(6):e0131357
pubmed: 26115223
eNeuro. 2018 Apr 6;5(2):
pubmed: 29632870
Am J Psychiatry. 2009 Jun;166(6):702-10
pubmed: 19411368
Psychopharmacology (Berl). 2008 Aug;199(3):457-80
pubmed: 18311558
Schizophr Res. 2016 Feb;170(2-3):278-84
pubmed: 26763628
Cortex. 2015 Aug;69:40-6
pubmed: 25967086
PLoS One. 2009 Aug 12;4(8):e6598
pubmed: 19672310
Soc Cogn Affect Neurosci. 2015 Jul;10(7):1015-9
pubmed: 25479792
Neuropsychology. 2016 Sep;30(6):685-96
pubmed: 27054437
Drug Saf. 1996 May;14(5):288-98
pubmed: 8800626
Neuropsychopharmacology. 2014 Sep;39(10):2366-75
pubmed: 24713613
Neural Netw. 2006 Oct;19(8):1302-14
pubmed: 16949252
Front Hum Neurosci. 2013 Apr 08;7:117
pubmed: 23580360
J Neurosci. 2003 Nov 26;23(34):10827-31
pubmed: 14645475
Front Behav Neurosci. 2018 Mar 23;12:52
pubmed: 29628879
Behav Brain Sci. 1999 Jun;22(3):491-517; discussion 518-69
pubmed: 11301519
Int J Neuropsychopharmacol. 2014 Dec;17(12):2045-56
pubmed: 24964269
Brain. 2018 May 1;141(5):1455-1469
pubmed: 29672668
Personal Neurosci. 2019 Jul 26;2:e3
pubmed: 32435738
Cereb Cortex. 2009 Oct;19(10):2240-7
pubmed: 19131436
Am J Epidemiol. 1986 Oct;124(4):678-83
pubmed: 3752061
Physiol Rev. 1998 Jan;78(1):189-225
pubmed: 9457173
Annu Rev Clin Psychol. 2017 May 8;13:471-495
pubmed: 28301764
Behav Brain Res. 2015 Mar 15;281:283-9
pubmed: 25546724
Biol Psychol. 2007 Jan;74(1):46-59
pubmed: 16904812
Neurosci Biobehav Rev. 2016 Jun;65:21-35
pubmed: 26959336
Neuropsychologia. 2018 Oct;119:417-423
pubmed: 30193845
J Abnorm Psychol. 2012 Aug;121(3):553-8
pubmed: 22775583
Cell Tissue Res. 2004 Oct;318(1):93-106
pubmed: 15503151
Cogn Affect Behav Neurosci. 2014 Jun;14(2):756-68
pubmed: 24323704
J Abnorm Psychol. 2014 May;123(2):387-97
pubmed: 24886012

Auteurs

Hanno Andreas Ohmann (HA)

Faculty of Psychology and Human Movement Science, Universität Hamburg, Hamburg, Germany.

Niclas Kuper (N)

Faculty of Psychology and Human Movement Science, Universität Hamburg, Hamburg, Germany.
Faculty of Psychology and Sports Science, Universität Bielefeld, Bielefeld, Germany.

Jan Wacker (J)

Faculty of Psychology and Human Movement Science, Universität Hamburg, Hamburg, Germany.

Classifications MeSH